In this work, we adopted a workflow including metabolic labeling, TAD-resin enrichment and MS quantification for a comprehensive understanding the changes of nascent proteins at the initial stage of drug treatment. Our investigation of nascent proteome alterations provided new insights into immediate responses of cancer cells to AZD9291 treatment, highlighting NNMT as a potential therapeutic target.